Prognostic and Predictive Factors for Renal Cell Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Translational Medicine

Background:

• Metastatic renal cell carcinoma (mRCC) is an aggressive cancer resistant to conventional therapies.
• Recent advances in understanding mRCC molecular pathogenesis have spurred targeted therapeutic development.
• Predictive biomarkers are crucial for optimizing mRCC treatment strategies.

Purpose of the Study:

• To provide an overview of clinical and molecular factors with predictive or prognostic value in mRCC.
• To emphasize the importance of integrating both factor types for individualized patient care.

Main Methods:

• Review of current literature on predictive and prognostic factors in mRCC.
• Analysis of molecular pathogenesis and its implications for targeted therapies.
• Synthesis of clinical data and molecular findings for treatment selection.

Main Results:

• Various molecular factors (tumor and host-derived, tissue and serum) show potential in predicting therapeutic benefit for mRCC.
• No single factor has been validated for routine clinical use in patient selection.
• Both clinical and molecular factors are associated with patient prognosis and treatment response.

Conclusions:

• Individualized treatment for mRCC requires parallel consideration of both clinical and molecular factors.
• Integrating diverse biomarkers can lead to more appropriate patient stratification and improved outcomes.
• Further validation of predictive markers is essential for routine clinical application in mRCC management.